R&D JP Morgan 2023 – Lisa Yañez At JP Morgan Week, pharmaphorum caught up with Lisa Yañez, CEO of Aerami Therapeutics.
Patients Join the dots between providers to untether DCT potential Dots must be joined between stakeholders for DCTs to drive efficiency and patient centricity.
R&D JP Morgan 2023 - Astrocyte Pharmaceuticals pharmaphorum spoke with Astrocyte's Kevin Sheth, William Korinek, and James D. Lechleiter
Patients Caring for rare: Celebrating Rare Disease Day 2023 Rare Disease Day is observed annually on what is considered the rarest day of the year.
R&D JP Morgan 2023 - Stefan Weber and Ravi Anand pharmaphorum sits down with Stefan Weber and Ravi Anand of neurology-focused biotech Newron.
R&D JP Morgan 2023 – Claudia Ulbrich Last month, pharmaphorum sat down with Claudia Ulbrich, CEO of Germany-based Cardior.
News Astellas pays $285m for Audax cancer drug, and other deals Astellas takes an option on a cancer immunotherapy developed by Audax for up to $1.34bn, with Gilead and Teva also adding to their pipelines.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
